Drug-Induced Vessel Remodeling in Bone Metastases as Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging and Vessel Size Imaging: A Longitudinal In vivo Study

Purpose: The aim of this study was to assess the antiangiogenic treatment effects of zoledronic acid (ZA) and sunitinib malate (SM) noninvasively in experimental breast cancer bone metastases by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and vessel size imaging. Experimental Design: Nude rats bearing bone metastases after inoculation of MDA-MB-231 breast cancer cells were treated with ZA (40 μg/kg weekly; n = 8 rats), SM (20 mg/kg daily; n = 8 rats), or their combination (ZA and SM; n = 8 rats) and compared with sham-treated controls (n = 10 rats). Vascular changes in bone metastases were longitudinally imaged in vivo using DCE-MRI [amplitude (A) and exchange rate coefficient (kep)] and vessel size imaging [blood volume (BV) and vessel size index (VI)]. In addition, antiresorptive and antitumor changes were assessed in these lesions by flat-panel volumetric computed tomography as well as morphologic MRI and diffusion-weighted imaging. Results: In bone metastases, significant changes in A, kep, BV, and VI in accordance with decreased blood volume and vessel permeability as well as with increased mean vessel diameters were observed after application of ZA and SM as compared with controls. In this longitudinal study, antiangiogenic changes preceded the inhibition of osteolysis and antitumor effects after treatment. Conclusions: These results indicate vessel remodeling in breast cancer bone metastases on ZA and SM treatment and implicate substantial effects on imaging and treatment of malignant bone lesions. Clin Cancer Res; 16(12); 3215–25. ©2010 AACR.

[1]  Fabian Kiessling,et al.  Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. , 2010, European journal of radiology.

[2]  L. Gurski,et al.  Mechanism of Metastasis to Bone: The Role of Bone Marrow Endothelium , 2010 .

[3]  W. Semmler,et al.  Imaging response to systemic therapy for bone metastases , 2009, European Radiology.

[4]  Wolfhard Semmler,et al.  Assessment of vascular remodeling under antiangiogenic therapy using DCE‐MRI and vessel size imaging , 2009, Journal of magnetic resonance imaging : JMRI.

[5]  M. Trikha,et al.  Inhibition of In Vivo Tumour Growth by the Blocking of Host αvβ3 and αIIbβ3 Integrins , 2009 .

[6]  H. Nagawa,et al.  Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. , 2009, The Journal of surgical research.

[7]  T. Plesner,et al.  A physical mechanism for coupling bone resorption and formation in adult human bone. , 2008, The American journal of pathology.

[8]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[9]  Fabian Kiessling,et al.  Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. , 2008, Neoplasia.

[10]  Timothy D Johnson,et al.  A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. , 2007, Neoplasia.

[11]  M. Caraglia,et al.  Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients , 2007, Clinical Cancer Research.

[12]  Bradford A Moffat,et al.  An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. , 2007, Cancer research.

[13]  P. Clézardin,et al.  Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. , 2007, Journal of the National Cancer Institute.

[14]  Fabian Kiessling,et al.  Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging , 2007, European Radiology.

[15]  T. Kalebic,et al.  Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation , 2006, British Journal of Cancer.

[16]  D. Ribatti,et al.  Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma , 2006, Oncogene.

[17]  M. Chávez-MacGregor,et al.  Angiogenesis in the Bone Marrow of Patients with Breast Cancer , 2005, Clinical Cancer Research.

[18]  F. Kiessling,et al.  Characterization of a rat model with site‐specific bone metastasis induced by MDA‐MB‐231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein , 2005, International journal of cancer.

[19]  M. Birch,et al.  Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone , 2005, British Journal of Cancer.

[20]  R. Strecker,et al.  Vessel size imaging in humans , 2005, Magnetic resonance in medicine.

[21]  D. Nam,et al.  Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[23]  Naoto T Ueno,et al.  Bone imaging in metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[25]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[26]  N. Pryer,et al.  SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model , 2004, Clinical & Experimental Metastasis.

[27]  P. Clézardin,et al.  Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity* , 2003, Journal of Biological Chemistry.

[28]  N. Pryer,et al.  Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. , 2003, Molecular cancer therapeutics.

[29]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[30]  L. Devy,et al.  Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid , 2002, Journal of Pharmacology and Experimental Therapeutics.

[31]  F. Orr,et al.  The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. , 2002, International journal of oncology.

[32]  H. Vloedgraven,et al.  Monitoring Metastatic Behavior of Human Tumor Cells in Mice with Species‐Specific Polymerase Chain Reaction: Elevated Expression of Angiogenesis and Bone Resorption Stimulators by Breast Cancer in Bone Metastases , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  M. Décorps,et al.  Vessel size imaging , 2001, Magnetic resonance in medicine.

[34]  Thiennu H. Vu,et al.  Matrix Metalloproteinase 9 and Vascular Endothelial Growth Factor Are Essential for Osteoclast Recruitment into Developing Long Bones , 2000, The Journal of cell biology.

[35]  Olav Haraldseth,et al.  Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging , 2000, Magnetic resonance in medicine.

[36]  S. Nishikawa,et al.  Vascular Endothelial Growth Factor Can Substitute for Macrophage Colony-Stimulating Factor in the Support of Osteoclastic Bone Resorption , 1999, The Journal of experimental medicine.

[37]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[38]  L R Schad,et al.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. , 1991, Journal of computer assisted tomography.